A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer

BJU International

Volumn 109, Issue 2, 2012, Pages 207-213

  Donovan, Michael J ^a   Khan, Faisal M ^a   Bayer Zubek, Valentina ^a   Powell, Douglas ^a   Costa, Jose ^a,b   Cordon Cardo, Carlos ^a,c  

^a Aureon Laboratories Inc   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

progression; prostate cancer; systems based models

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; 4',6 DIAMIDINO 2 PHENYLINDOLE; ANDROGEN RECEPTOR; CD34 ANTIGEN; CYTOKERATIN 18; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; PROTEIN KINASE B; PROTEIN P63;

AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; VALIDATION PROCESS;

AGED; ALGORITHMS; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MODELS, BIOLOGICAL; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84655169654     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10316.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Andriole GL, Crawford ED, Grubb RL III, et al,. Mortality results from a randomized prostate-cancer screening trail. N Engl J Med 2009; 360: 1310-9
3. Schroder FH, Hugossson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
4. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW,. Comparison of nomograms and other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008; 14: 4400-7
5. Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ,. Prostate cancer: the new landscape. Curr Opin Urol 2009; 19: 154-60
6. Cooperberg MR, Konety BR,. Management of localized prostate cancer in men over 65 years. Curr Opin Urol 2009; 19: 309-14
7. Cordon-Cardo C, Kotsianti A, Verbel DA, et al,. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007; 117: 1876-83 (Pubitemid 47036321)
8. Donovan MJ, Hamann S, Clayton M, et al,. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008; 26: 3923-9
9. Donovan MJ, Khan FM, Fernandez G, et al,. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 2009; 182: 125-32
10. Johansson JE, Andren O, Andersson SO, et al,. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-9 (Pubitemid 38725420)
11. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101 (Pubitemid 40617061)
12. Cuzick J, Fisher G, Kattan MW, et al,. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer 2006; 95: 1186-94 (Pubitemid 44658482)
13. Berney DM, Gopalan A, Kudahetti S, et al,. Ki67 and outcome in clinically localized prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93
14. Khan FM, Bayer-Zubek V,. Support vector regression for censored data [SVRc]: a novel tool for survival analysis. Proceedings of the Eighth IEEE international conference on data mining. ICDM 2008; 50: 863-8
15. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-9 (Pubitemid 47224952)
16. Hoffman RM,. Randomized trial results did not resolve controversies surrounding prostate cancer screening. Curr Opin Urol 2010; 20: 189-93
17. Bill-Axelson A, Holmberg L, Filen F, et al,. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54
18. Kattan MW, Cuzick J, Fisher G, et al,. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112: 69-74
19. Inoue T, Segawa T, Shiraishi T, et al,. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332-7 (Pubitemid 41138093)
20. Bubendorf L, Tapia C, Gasser TC, et al,. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949-54 (Pubitemid 28422042)
21. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta KJ,. Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens. J Natl Cancer Inst 2000; 92: 1941-2 (Pubitemid 32036925)
22. Pollack A, DeSilvio M, Khor LY, et al,. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004; 22: 2133-40 (Pubitemid 41095146)
23. Aaltomaa S, Karja V, Lipponen P, et al,. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 2006; 26: 4873-8 (Pubitemid 46032126)
24. Ayala G, Thompson T, Yang G, et al,. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004; 10: 6572-8 (Pubitemid 39346553)
25. Kreisberg JI, Malik SN, Prihods TJ, et al,. Phosphorylation of Akt [Ser473] is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-6 (Pubitemid 39006542)
26. Bedolla R, Prihoda TJ, Kreisberg JI, et al,. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-7 (Pubitemid 47037592)
27. Blanco-Aparicio C, Renner O, Leal JF, Carnero A,. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-86 (Pubitemid 47243536)
28. Sboner A, Demichelis F, Calza S, et al,. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010; 3: 2-12
29. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J,. Phosphorylation of the androgen receptor is associated with reducedsurvival in hormone-refractory prostate cancer patients. Br J Cancer 2008; 98: 1094-101 (Pubitemid 351399795)